A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-α administered as a 24-hour weekly infusion schedule in patients with advanced cancer

Author： Advani Ranjana   Lum Bert   Fisher George   Halsey Joanne   Geary Richard   Holmlund Jon   Kwoh T.   Dorr F.   Sikic Branimir  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.23, Iss.5, 2005-10, pp. : 467-477

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy

By Ramanathan Ramesh  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1591-1596

Springer Publishing Company

Access to resources Recommend Favorite

The Role of Protein Kinase C-alpha (PKC-) in Cancer and its Modulation by the Novel PKC--Specific Inhibitor Aprinocarsen

By  

Current Pharmaceutical Design, Vol. 10, Iss. 16, 2004-06 ,pp. : 1923-1936

Bentham Science Publishers

Access to resources Recommend Favorite

NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies

By Dent S.   Gelmon K.   Chi K.   Jonker D.   Wainman N.   Capier C.   Chen E.   Lyons J.   Seymour L.  

Investigational New Drugs, Vol. 31, Iss. 6, 2013-12 ,pp. : 1522-1529

Springer Publishing Company

Access to resources Recommend Favorite

A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advanced solid cancers

By Goel Sanjay   Desai Kavita   Macapinlac Manuel   Wadler Scott   Goldberg Gary   Fields Abbie   Einstein Mark   Volterra Fabio   Wong Benny   Martin Russell   Mani Sridhar  

Investigational New Drugs, Vol. 24, Iss. 2, 2006-03 ,pp. : 125-134

Springer Publishing Company

Access to resources Recommend Favorite

A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors

By Burris Howard   Jones Suzanne   Williams Daphne   Kathman Steven   Hodge Jeffrey   Pandite Lini   Ho Peter   Boerner Scott   LoRusso Patricia  

Investigational New Drugs, Vol. 29, Iss. 3, 2011-06 ,pp. : 467-472

Springer Publishing Company

Access to resources Recommend Favorite